Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19

Am J Respir Crit Care Med. 2020 Nov 1;202(9):1304-1308. doi: 10.1164/rccm.202007-2778LE.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Betacoronavirus*
  • COVID-19
  • Complement Inactivator Proteins / administration & dosage*
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / epidemiology
  • Female
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / epidemiology
  • SARS-CoV-2
  • Treatment Outcome

Substances

  • Complement Inactivator Proteins